Clinical Study of Early Application of Mirabegron after Transurethral Holmium Laser Enucleation of Prostate for Benign Prostatic Hyperplasia with Overactive Bladder
Objective:To investigate the efficacy and safety of Mirabegron in the early application after transurethral holmium laser enucleation of prostate (HoLEP) for benign prostatic hyperplasia (BPH) with overactive bladder (OAB).Method:Seventy-two patients with BPH and OAB who admitted to Wujin Hospital Affiliated to Jiangsu University from January 2020 to January 2022 were selected as the study objects,they were randomly divided into two groups,all patients were underwent HoLEP under general anesthesia,thirty-six patients in the observation group was given Mirabegron Sustained-release Tablets,thirty-six patients in the control group were not given drug treatment,and three patients in the observation group withdrew from the study due to the novel coronavirus epidemic.The incidence of complications,overactive bladder symptom score (OABSS),quality of life (QOL),international prostate symptom score (IPSS),maximum urinary flow rate (Qmax),residual urine volume (PVR) and adverse drug reactions were compared between two groups.Result:At 4 weeks after operation,the QOL scores,voiding symptom IPSS (V-IPSS),total IPSS (T-IPSS),maximum urinary flow rate (Qmax) and residual urine volume (PVR) of two groups were improved compared with those before operation,and the differences were statistically significant (P<0.05);the OABSS score and urine storage symptom IPSS (S-IPSS) score of the control group at 4 weeks after operation were lower than those before operation,but the difference was not statistically significant (P>0.05);the OABSS score and S-IPSS score of the observation group at 4 weeks after operation were lower than those before operation and those of the control group after operation,and the differences were statistically significant (P<0.05);the QOL score and T-IPSS score of the observation group at 4 weeks after operation were lower than those of the control group,and the differences were statistically significant (P<0.05);however,there were no significant differences in the V-IPSS score,Qmax and PVR between two groups at 4 weeks after operation (P>0.05).There were 2 cases (6.1％) of constipation in the observation group during oral administration of Mirabegron,and 1 case (2.8％) of constipation in the control group,there was no significant difference between two groups (P>0.05).Conclusion:Early application of Mirabegron after HoLEP can further alleviate lower urinary tract symptoms in patients with BPH and OAB without affecting urinary function.
Prostatic hyperplasiaOveractive bladderTransurethral holmium laser enucleation of prostateMirabegron
万方数据
维普
